{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:04:04Z","timestamp":1785301444082,"version":"3.55.0"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Lineage switch (LS), defined as a change in leukemic lineage during the disease course, is a rare but clinically significant event in acute leukemia and is typically associated with poor prognosis. Although LS has been increasingly reported following targeted immunotherapies, the clonal mechanisms underlying this phenomenon remain incompletely understood, particularly in cases without KMT2A rearrangement. We report a case of LS from B-precursor acute lymphoblastic leukemia (BCP-ALL) to acute myeloid leukemia (AML) following treatment with the CD22-targeted antibody\u2013drug conjugate inotuzumab ozogamicin. To elucidate the clonal architecture underlying LS, targeted next-generation sequencing was performed on bone marrow samples obtained at multiple time points throughout the disease course. Genomic analysis demonstrated that the lymphoid and myeloid disease phases shared ancestral genetic alterations but displayed distinct mutational profiles. At the time of LS, TP53 and SMC1A mutations newly emerged, whereas only a subset of mutations detected at ALL relapse was retained. These findings suggest that the AML phase most likely resulted from the selective expansion of a genetically distinct subclone derived from a common progenitor, rather than the direct transdifferentiation of the dominant ALL clone, consistent with immunotherapy-driven clonal selection. Longitudinal genomic profiling revealed stepwise clonal evolution during disease progression, supporting a model of immunotherapy-driven clonal selection leading to LS. This case provides molecular evidence suggesting that immune-targeted therapy can promote expansion of minor pre-existing subclones with alternative lineage potential within a common progenitor even in non-KMT2A-rearranged leukemia. Our findings highlight the importance of comprehensive genomic monitoring during immunotherapy to identify therapy-resistant subclones and better understand mechanisms of lineage plasticity in acute leukemia.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1828617","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:48:35Z","timestamp":1785300515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Immune-driven clonal selection underlying lineage switch from B-Precursor acute lymphoblastic leukemia to acute myeloid leukemia following inotuzumab ozogamicin"],"prefix":"10.3389","volume":"17","author":[{"given":"Kaori","family":"Kondo","sequence":"first","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichi","family":"Sadato","sequence":"additional","affiliation":[{"name":"Clinical Research and Trials Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Itabashi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nippon Medical School Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Ueda","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Nippon Medical School Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuko","family":"Hirama","sequence":"additional","affiliation":[{"name":"Clinical Research and Trials Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Shimabukuro","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atushi","family":"Jinguji","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Shingai","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Toya","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Toubai","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital","place":["Tokyo, Japan"]},{"name":"Clinical Research and Trials Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Harada","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital","place":["Tokyo, Japan"]},{"name":"Laboratory of Oncology, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Harada","sequence":"additional","affiliation":[{"name":"Clinical Research and Trials Center, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Doki","sequence":"additional","affiliation":[{"name":"Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23266","article-title":"Lineage switch in childhood acute leukemia: an unusual event with poor outcome","volume":"87","author":"Rossi","year":"2012","journal-title":"Am J Hematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026655","article-title":"Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia","volume":"146","author":"Silbert","year":"2025","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/406796","article-title":"Lineage switching in acute leukemias: a consequence of stem cell plasticity","volume":"2012","author":"Dorantes-Acosta","year":"2012","journal-title":"Bone Marrow Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320","article-title":"CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity","volume":"7","author":"Jacoby","year":"2016","journal-title":"Nat Commun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018018093","article-title":"Spontaneous reversion of a lineage switch following an initial blinatumomab-induced ALL-to-AML switch in MLL-rearranged infant ALL","volume":"2","author":"W\u00f6lfl","year":"2018","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255257","article-title":"Archival bone marrow smears are useful in targeted next-generation sequencing for diagnosing myeloid neoplasms","volume":"16","author":"Sadato","year":"2021","journal-title":"PLoS One"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284953","article-title":"Impact of genetic alterations on central nervous system progression of primary vitreoretinal lymphoma","volume":"109","author":"Yoshifuji","year":"2024","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015036","article-title":"Epigenetic regulator genes direct lineage switching in MLL\/AF4 leukemia","volume":"140","author":"Tirtakusuma","year":"2022","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02405-w","article-title":"Stable clonal contribution of lineage-restricted stem cells to human hematopoiesis","volume":"57","author":"Yoshizato","year":"2025","journal-title":"Nat Genet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104783","article-title":"Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: a scoping review of safety and efficacy","volume":"213","author":"Dali","year":"2025","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/ajh.27655","article-title":"TP53 -mutated myeloid neoplasms: 2024 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shah","year":"2025","journal-title":"Am J Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-03951-z","article-title":"Transplantation outcomes of TP53-mutant AML and MDS: a single transplantation center experience of 63 patients","volume":"121","author":"Masuda","year":"2025","journal-title":"Int J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01016-9","article-title":"Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT","volume":"56","author":"Najima","year":"2021","journal-title":"Bone Marrow Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1828617\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:48:59Z","timestamp":1785300539000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1828617\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":13,"alternative-id":["10.3389\/fimmu.2026.1828617"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1828617","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"article-number":"1828617"}}